Alzheimer's treatment shows unique results

October 19, 2018, Uppsala University
Alzheimer’s treatment shows unique results
Despite his team’s successes, Lars Lannfelt does not want to speculate on when an approved treatment can be available for health care. Credit: Johan Wahlgren

In late July there were reports in the media from a conference in Chicago about Alzheimer's disease. The focus of journalists' attention was a new study of how the progression of the disease is affected by the BAN2401 antibody, a Swedish product developed by Lars Lannfelt, Senior Professor of Geriatrics at the Department of Public Health and Caring Sciences.

"We have tested the antibody in various doses on 856 patients on three continents with better results than we even dared to hope for. After only six months we observed positive results, and after 18 months 81 per cent of the group receiving the highest dosage showed lower levels of amyloid beta than the level we measure in Alzheimer's disease," says Lannfelt.

A change in genetic material identified

The idea for the antibody originated back in the 1990s, when the team identified a change in the of a Swedish family that had been severely afflicted by Alzheimer's disease. The mutation indicated that the cause seemed to be a soluble, early form of amyloid beta molecules, known as protofibrils, which give rise to plaque in the brain.

"With this new knowledge, we chose to focus on these protofibrils, which we believed were the form of that causes the most damage. In 2005 we developed our antibody, and today I am extremely pleased with what we have achieved, for the sake of the patients and my many colleagues over the years and for Swedish research," says Lannfelt.

Modifications of the antibody

In 2003 Lannfelt and former research colleague Pär Gellerfors founded the BioArctic biotechnology company as a platform for pharmaceutical development. A significant part of the modifications of the antibody were carried out there, and when the results of the current study were made public, the shares soared in the stock market. Suddenly Lannfelt and Gellerfors saw their faces on Swedish business magazines accompanied by headlines such as "Swedish Alzheimer researchers became billionaires in two days".

"I do not see any problem with researchers benefiting from their innovations, but I find it annoying that the Swedish press has chosen to focus on the money rather than the medical innovation and its importance for patients. I have never been motivated by economic interests, and I will retain my shareholding to remain a guiding force in BioArctic's continued development and to help maintain the right course."

Today BioArctic is preparing for the Phase III study every pharmaceutical product must undergo before it reaches the market. At its side BioArctic has Eisai, Japan's pharmaceutical giant, which is assisting with funding and implementation. The goal is to go ahead as early as 2019, but despite BioArctic's successes, Lannfelt does not want to speculate on when an approved treatment can be available for health care.

"I have learned that it is far too easy to be optimistic about timing, but with the results we demonstrate in combination with minimal side effects, I believe we will be able to offer the first approved pharmaceutical for Alzheimer's disease. This would mean enormous socio-economic savings, and above all great hope for all the patients and relatives that we can help enjoy a better old age."

Explore further: Scientists closer to slowing progression of Alzheimer's

Related Stories

Scientists closer to slowing progression of Alzheimer's

September 7, 2018
A breakthrough by Wits scientists could see patients with Alzheimer's use a nasal spray to slow down the progression of the disease, the main cause of dementia.

Antibody provide a more exact Alzheimer's diagnosis radioactive tracers

February 19, 2016
For the first time, researchers have succeeded in passing an antibody through the blood-brain barrier to act as a tracer for PET imaging of the brain. This resulted in more precise information being obtained than with regular ...

Alzheimer's disease – don't give up on plaque-busting drugs just yet

September 28, 2018
Alzheimer's disease is associated with a build-up of plaques in the brain called amyloid beta. These plaques are thought to lead to a loss of neurons, which then causes the classic symptoms of the disease – including memory ...

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Possible solution for side effect of Alzheimer's immunotherapy treatment

November 5, 2015
It is estimated that 46.8 million people worldwide are living with dementia, with Alzheimer's disease the most common form.

Recommended for you

New information on the pathological mechanisms of Alzheimer's disease

November 21, 2018
Researchers at the University of Helsinki have discovered a mechanism by which harmful tau protein aggregates are transmitted between neurons. Alongside amyloid plaques, tau aggregates in the brain are a significant factor ...

DNA vaccine reduces both toxic proteins linked to Alzheimer's

November 20, 2018
A DNA vaccine tested in mice reduces accumulation of both types of toxic proteins associated with Alzheimer's disease, according to research that scientists say may pave the way to a clinical trial.

For Down syndrome adults, death and dementia often come together

November 19, 2018
(HealthDay)—Seven in 10 people with Down syndrome show evidence of dementia when they die, new research from Britain reveals.

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.